with an IGAxBSA-50 achievement was also significantly greater among HP/TAZ-treated participants than those treated with vehicle (58.1% vs 26.3%, respectively; P<0.001).
Safety Evaluations
Of the participants treated with HP/TAZ lotion, 36.1% reported treatment-emergent AEs (TEAEs) compared with 22.9% of those treated with vehicle; TEAEs were categorized as mild or moderate in severity in most patients (Table 2). Only 3 participants (2.1%) reported serious AEs following treatment with HP/TAZ lotion. The most common treatment-related TEAEs (incidence ≥2%) in HP/TAZ-treated participants were contact dermatitis (7.6%), skin atrophy (2.8%), folliculitis (2.8%), and excoriation (2.1%); no AEs of striae were identified. In the 4 patients with a TEAE of skin atrophy, all cases were mild or moderate in severity and were resolved/resolving with either a dose reduction or no change in treatment. In the vehicle-group, frequently reported treatment-related TEAEs were pruritus, skin burning sensation, and burning sensation (nervous system disorder; 2.9% for all).
DISCUSSION
This pooled post hoc analysis of 2 phase 3 studies evaluated the
efficacy and safety of HP/TAZ lotion in patients with moderate to
severe plaque psoriasis of the lower extremities (target lesion of
the leg). At the end of the 8-week treatment period, HP/TAZ lotion
demonstrated significant efficacy in improving signs of psoriasis
(erythema, plaque elevation, and scaling) at the leg target le-
